[ACST] Acasti Pharma, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ACST
ACST is in the long-term down -97% below S&P in 10 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 10.71 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | ROE | ROI | ||||
| Current Ratio | Quick Ratio | Long Term Debt/Equity | Debt Ratio | ||||
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | Gross Profit | ||||
| Net Profit | Operating Profit | Total Assets | Total Current Assets | ||||
| Total Current Liabilities | Total Debt | Total Liabilities | Total Revenue |
Technical Data
| High 52 week | 3.1 | Low 52 week | 0.63 | Last close | 0.71 | Last change | 1.59% |
| RSI | 36.35 | Average true range | 0.04 | Beta | 0.3 | Volume | 4.94 M |
| Simple moving average 20 days | -2.49% | Simple moving average 50 days | -23.16% | Simple moving average 200 days | -39.8% |
Performance Data
| Performance Week | 7.92% | Performance Month | -34.26% | Performance Quart | -31.73% | Performance Half | -44.96% |
| Performance Year | -43.2% | Performance Year-to-date | -24.69% | Volatility daily | 6.55% | Volatility weekly | 14.65% |
| Volatility monthly | 30.03% | Volatility yearly | 104.04% | Relative Volume | 5202.7% | Average Volume | 196.58 K |
| New High | New Low |
News
2019-08-14 08:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
2019-08-09 08:00:00 | Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
2019-08-07 08:00:00 | Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
2019-07-25 15:42:52 | Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital
2019-07-05 08:35:12 | Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
2019-06-26 11:08:45 | Acasti Pharma Trades Higher Despite 'Material Uncertainty'
2019-06-26 11:00:00 | Acasti Pharma, Inc. to Host Earnings Call
2019-06-26 08:05:00 | Acasti Pharma Provides Fiscal 2019 Year-End Business Update
2019-06-24 09:00:00 | Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
2019-06-19 08:00:00 | Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call
2019-06-04 09:15:00 | Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
2019-05-23 17:00:00 | Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
2019-05-21 07:30:00 | Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
2019-05-15 07:55:00 | Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
2019-05-10 07:30:00 | Acasti Settles Claims with Former Chief Executive Officer
2019-04-24 08:00:00 | Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
2019-04-15 09:15:00 | Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
2019-04-01 09:20:53 | Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
2019-03-26 08:30:00 | Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
2019-03-13 08:30:00 | Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
2019-02-21 09:15:00 | Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50
2019-02-14 14:57:21 | Acasti: Fiscal 3Q Earnings Snapshot
2019-02-14 08:05:00 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
2019-02-08 08:00:00 | Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs
2019-01-09 08:00:00 | Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
2018-12-28 09:55:02 | Generic Industry on Path to Recovery: 3 Hot Picks for 2019
2018-12-20 08:00:00 | Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
2018-11-27 07:00:00 | Acasti Pharma to Present at the 11th Annual LD Micro Main Event
2018-11-14 08:53:13 | Acasti: Fiscal 2Q Earnings Snapshot
2018-11-14 08:00:00 | Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
2018-11-07 08:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
2018-10-23 09:00:11 | Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
2018-10-11 07:30:00 | Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
2018-10-10 08:05:00 | Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review
2018-10-04 09:35:40 | Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
2018-10-04 07:59:50 | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut
2018-10-03 16:23:12 | Acasti Pharma Announces Public Equity Offering
2018-10-03 16:23:11 | Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares
2018-10-01 17:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
2018-09-28 08:17:00 | Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma
2018-09-24 08:00:00 | Acasti Pharma Appoints Jean-François Boily as Vice President of Finance
2018-09-18 08:52:02 | Acasti Pharma Provides Clinical and Market Update
2018-08-29 16:05:00 | Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
2018-08-14 13:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
2018-08-14 08:39:31 | Acasti: 2Q Earnings Snapshot
2018-07-31 17:09:05 | Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan
2018-07-24 09:15:11 | Benzinga Pro's 5 Stocks To Watch Today